Exhibit 99.1

August 2, 2017

TransEnterix, Inc. Reports Operating Results for the Second Quarter 2017

RESEARCH TRIANGLE PARK, N.C.—(BUSINESS WIRE) — TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2017.

Recent Highlights

-The Company sold a SenhanceTM Surgical Robotic System to Saitama Medical University International Medical Center
-The Company submitted its 510(k) application for the Senhance Surgical Robotic System to FDA
-The Company raised approximately $23.2 million through an equity financing

-The Company refinanced its debt, securing up to $17.0 million in debt financing

-In July, the Senhance platform was used in the first-ever robotic micro-laparoscopic surgeries using 3mm instruments
-In July, the Novadaq Pinpoint Fluorescence Imaging system was used in conjunction with the Senhance platform

“We are very pleased with the progress we made during the quarter on our key strategic priorities, including the steps taken towards achieving 510(k) clearance for the Senhance by the end of 2017,” said Todd M. Pope, President and Chief Executive Officer of TransEnterix. “We are also encouraged by the continued momentum in clinical utilization in Europe, and now globally with our sale in Japan. In addition, we have been able to leverage the open architecture of the Senhance to incorporate cutting edge technologies into the platform, setting a new standard for minimally invasive robotic surgery.”

Commercial and Clinical Update
In the second quarter, the Company sold a Senhance Robotic Surgery System to the Saitama Medical University International Medical Center located in the Saitama Prefecture in the Greater Tokyo region. The Senhance System was purchased in Japan under a physician import license, which allows cutting-edge medical devices to be directly purchased by Japanese physicians. Japan is the second largest market for medical devices as well as robotic assisted surgery devices. The Senhance does not have broader market approval for sale in Japan.

As of June 30, 2017, the Company had eight Senhance systems installed in France, Germany, Italy, the United Kingdom, and Japan. Within these eight hospitals, 21 surgeons performed surgery in the second quarter across gynecology, colorectal, general surgery, urology, and thoracic specialties.

In July, the Senhance platform was used in the first-ever robotic micro-laparoscopic surgeries utilizing 3mm instruments. Cases were performed at multiple clinical sites and included ovarian cystectomies, endometrial excisions, total laparoscopic hysterectomies, bilateral salpingo-oophorectomies and cholecystectomies. The Company expects to fully launch its 3mm instruments in the fourth quarter in CE Mark countries.

In July, the Novadaq PinPoint Endoscopic Fluorescence Imaging System was used in conjunction with the Senhance platform in multiple general surgical and gynecologic procedures. The open architecture of the Senhance platform allowed us to rapidly integrate this system so that surgeons can benefit from utilizing this leading fluorescence imaging technology.

Financial Highlights
For the three months ended June 30, 2017, the Company reported revenue of $1.6 million, primarily related to the sale of one Senhance during the quarter.

For the three months ended June 30, 2017, total operating expenses were $15.4 million, as compared to $80.7 million in the three months ended June 30, 2016. The prior year quarter included approximately $67.4 million of non-recurring impairment charges.

For the three months ended June 30, 2017, net loss was $14.7 million, or $0.11 per share, as compared to $80.1 million, or $0.70 per share, in the three months ended June 30, 2016.

The Company had cash, cash equivalents and restricted cash of approximately $36.2 million as of June 30, 2017. In the second quarter, the Company completed an equity offering with approximately $23.2 million in net proceeds, and refinanced its debt. With these funding actions, the Company expects to fund its operations into the first quarter of 2018. The equity offering also included Series A warrants that will expire ten days after the announcement of an FDA clearance of the Senhance. Assuming that these warrants are exercised, the Company will receive another $25.0 million, which the Company expects will fund its operations into late 2018.

Conference Call
TransEnterix, Inc. will host a conference call on Wednesday, August 2, 2017 at 4:30 PM ET to discuss its second quarter 2017 operating and financial results. To listen to the conference call on your telephone, please dial (888) 852-6561 for domestic callers or (719) 325-2281 for international callers and reference TransEnterix Call approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the Company’s website.

About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The Company is focused on the commercialization of the Senhance™ Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Forward-Looking Statements
This press release includes statements relating to our second quarter 2017 results, the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including: whether the FDA will provide regulatory clearance of our Senhance 510(k) submission by the end of 2017; whether our commercialization plans and the development of our pipeline will be successful; whether TransEnterix will fully launch its 3mm instruments in the 2017 fourth quarter in CE Mark countries; whether existing cash and cash equivalents will fund operations into the first quarter of 2018; and whether the Company is able to fund its operations into late 2018 resulting from the exercise of its Series A Common Stock Warrants. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed on March 6, 2017, and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

TransEnterix, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands except per share amounts)
(Unaudited)
 

                                                                 
            Three Months Ended   Six Months Ended
            June 30,   June 30,
            2017           2016   2017   2016
Revenue
          $ 1,584           $           $ 3,530           $
Cost of revenue
          972                     2,306          
 
                                                               
Gross profit
          612                     1,224          
 
                                                               
Operating Expenses
                                                               
Research and development
          5,070           6,364           11,925           14,749
Sales and marketing
          3,749           1,306           7,472           2,989
General and administrative
          2,719           2,895           5,768           5,134
Amortization of intangible assets
          1,687           1,786           3,323           3,603
Change in fair value of contingent consideration
          (774 )           944           453           1,800
Change in fair value of warrant liabilities
          2,326                     2,326          
Issuance costs for warrants
          627                     627          
Inventory write-down related to restructuring
                    2,565                     2,565
Restructuring and other charges
                    3,085                     3,085
Goodwill impairment
                    61,784                     61,784
Total Operating Expenses
          15,404           80,729           31,894           95,709
 
                                                               
Operating Loss
          (14,792 )           (80,729 )           (30,670 )           (95,709 )
 
                                                               
Other Expense
                                                               
Interest expense, net
          (622 )           (489 )           (956 )           (1,067 )
Other (expense) income
          (40 )           95           (100 )           95
 
                                                               
Total Other Expense, net
          (662 )           (394 )           (1,056 )           (972 )
 
                                                               
Loss before income taxes
          $ (15,454 )           $ (81,123 )           $ (31,726 )           $ (96,681 )
Income tax benefit
          741           992           1,599           3,637
 
                                                               
Net loss
          $ (14,713 )           $ (80,131 )           $ (30,127 )           $ (93,044 )
 
                                                               
Other comprehensive income (loss)
                                                               
Foreign currency translation gain (loss)
          5,430           (2,286 )           6,563           1,510
 
                                                               
Comprehensive loss
          $ (9,283 )           $ (82,417 )           $ (23,564 )           $ (91,534 )
 
                                                               
Net loss per share — basic and diluted
          $ (0.11 )           $ (0.70 )           $ (0.24 )           $ (0.85 )
 
                                                               
Weighted average common shares outstanding — basic and diluted
          132,386           114,319           127,052           109,290
 
                                                               

TransEnterix, Inc.
Consolidated Balance Sheets
(in thousands, except share amounts)

 (Unaudited)

                                         
    June 30,   December 31,
    2017   2016
Assets
                                       
Current Assets
                                       
Cash and cash equivalents
          $ 29,741                   $ 24,165
Accounts receivable, net
          1,665                   621
Inventories
          9,464                   7,883
Interest receivable
          13                   12
Other current assets
          7,231                   5,335
 
                                       
Total Current Assets
          48,114                   38,016
 
                                       
Restricted cash
          6,419                   10,425
Accounts receivable, net of current portion
                            266
Property and equipment, net
          6,404                   5,772
Intellectual property, net
          37,170                   37,090
In-process research and development
          17,276                   15,920
Goodwill
          70,310                   68,697
Other long term assets
          146                   63
 
                                       
Total Assets
          $ 185,839                   $ 176,249
 
                                       
Liabilities and Stockholders’ Equity
                                       
Current Liabilities
                                       
Accounts payable
          $ 2,219                   $ 3,984
Accrued expenses
          8,221                   8,206
Contingent consideration – current portion
          6,918                   10,502
Notes payable — current portion, net of debt discount
                            7,997
 
                                       
Total Current Liabilities
          17,358                   30,689
Long Term Liabilities
                                       
Contingent consideration – less current portion
          11,108                   12,298
Notes payable — less current portion, net of debt discount
          12,896                   4,995
Warrant liabilities
          11,041                  
Net deferred tax liabilities
          9,614                   10,397
 
                                       
Total Liabilities
          62,017                   58,379
Commitments and Contingencies
                                       
Stockholders’ Equity
                                       
Common stock $0.001 par value, 750,000,000 shares authorized at June 30, 2017, and December 31, 2016; 148,538,492 and 115,781,030 shares issued at June 30, 2017 and December 31, 2016, respectively; and 148,536,356 and 115,687,351 shares outstanding at June 30, 2017 and December 31, 2016, respectively
          148                   115
Additional paid-in capital
          455,853                   426,609
Accumulated deficit
          (332,971 )                   (302,844 )
Treasury stock at cost, 2,136 and 93,679 shares at June 30, 2017 and December 31, 2016, respectively
          (2 )                   (241 )
Accumulated other comprehensive income (loss)
          794                   (5,769 )
 
                                       
Total Stockholders’ Equity
          123,822                   117,870
 
                                       
Total Liabilities and Stockholders’ Equity
          $ 185,839                   $ 176,249
 
                                       

TransEnterix, Inc.
Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
 

                                                         
            Six Months Ended
            June 30,
            2017                   2016
Operating Activities
                                                       
Net loss
          $   (30,127 )                   $   (93,044 )
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
                                                       
Depreciation
                  1,142                           1,052
Amortization of intangible assets
                  3,323                           3,603
Amortization of debt discount and debt issuance costs
                  43                           99
Stock-based compensation
                  3,679                           2,477
Inventory write-down related to restructuring
                                            2,565
Non-cash restructuring and other charges
                                            2,551
Goodwill impairment
                                            61,784
Deferred tax benefit
                  (1,580 )                           (3,657 )
Loss on extinguishment of debt
                  308                          
Change in fair value of warrant liabilities
                  2,326                          
Change in fair value of contingent consideration
                  453                           1,800
Changes in operating assets and liabilities:
                                                       
Accounts receivable
                  (487 )                          
Interest receivable
                  39                           (13 )
Inventories
                  (862 )                           (3,983 )
Other current and long term assets
                  (1,473 )                           (213 )
Accounts payable
                  (1,909 )                           (2,497 )
Accrued expenses
                  (390 )                           (60 )
 
                                               
Net cash and cash equivalents used in operating activities
                  (25,515 )                           (27,536 )
 
                                               
Investing Activities
                                                       
Purchase of property and equipment
                  (1,397 )                           (517 )
Purchase of intellectual property
                  (398 )                          
 
                                               
Net cash and cash equivalents used in investing activities
                  (1,795 )                           (517 )
 
                                               
Financing Activities
                                                       
Payment of debt
                  (13,343 )                           (3,078 )
Proceeds from issuance of debt and warrants
                  13,196                          
Proceeds from issuance of common stock and warrants, net of issuance costs
                  29,193                           57,637
Taxes paid related to net share settlement of vesting of restricted stock units
                  (168 )                           (130 )
Proceeds from exercise of stock options and warrants
                                            165
 
                                               
Net cash and cash equivalents provided by financing activities
                  28,878                           54,594
 
                                               
Effect of exchange rate changes on cash and cash equivalents
                  2                           (92 )
 
                                               
Net increase in cash, cash equivalents and restricted cash
                  1,570                           26,449
Cash, cash equivalents and restricted cash, beginning of period
                  34,590                           38,449
 
                                               
Cash, cash equivalents and restricted cash, end of period
                  $ 36,160                           $ 64,898
 
                                       
Supplemental Disclosure for Cash Flow Information
                                                       
Interest paid
                  $ 368                           $ 713
Supplemental Schedule of Noncash Investing Activities
                                                       
Transfer of inventory to property and equipment
                                            $ 1,823
Issuance of common stock as contingent consideration
                  $ 5,227                          
Relative fair value of warrants issued with debt
          $   300                          

1

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1-443-213-0501
invest@transenterix.com
or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
or
(For US) Hannah Dunning, +1-415-618-8750
TransEnterix-SVC@sardverb.com

2


The following information was filed by Transenterix Inc. (TRXC) on Friday, August 4, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Transenterix Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Transenterix Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account